Addrenex Pharmaceuticals (Acquired by Sciele Pharma)

17 articles with Addrenex Pharmaceuticals (Acquired by Sciele Pharma)

• Sciele Pharma, Inc., a Shionogi & Co., Ltd. Company, to Acquire Addrenex Pharmaceuticals, a U.S. Specialty Pharmaceutical Company

  11/16/2009

• Addrenex Pharmaceuticals Announces Licensing Agreement With Dream Pharma

  8/5/2009

• Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy

  5/13/2009

• Sciele Pharma, Inc. and Addrenex Pharmaceuticals Announce Positive Phase III Clinical Results of Clonicel Used in Combination with Stimulants to Treat ADHD

  4/23/2009

• Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication

  4/23/2009

• Sciele Pharma, Inc. Announces That Addrenex Pharmaceuticals Initiates Phase II Clinical Trial of ADX415 for the Treatment of Hypertension

  10/23/2008

• Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415

  10/23/2008

• Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD

  9/11/2008

• Sciele Pharma, Inc. and Addrenex Pharmaceuticals Announce Positive Phase III Clinical Results of Clonicel for ADHD

  9/10/2008

• Addrenex Pharmaceuticals' New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation

  8/20/2008

• Addrenex Pharmaceuticals Licenses New Compound to Sciele Pharma, Inc. for the Treatment of Hypertension and Other Potential Indications

  7/2/2008

• Sciele Pharma, Inc. Signs Agreement with Addrenex Pharmaceuticals To Develop and Market ADX415 for the Treatment of Hypertension

  7/1/2008

• Sciele Pharma, Inc. Announces FDA Acceptance of NDA for Addrenex Pharmaceuticals' CloniBID to Treat Hypertension

  4/22/2008

• Sciele Pharma, Inc. and Addrenex Pharmaceuticals Announce NDA Submission of CloniBID to Treat Hypertension

  2/20/2008

• Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension

  2/20/2008

• Sciele Pharma, Inc. and Addrenex Pharmaceuticals Announce Initiation of Pivotal Phase III Trials for Clonicel for ADHD

  10/30/2007

• Sciele Pharma, Inc. Signs Agreement with Addrenex Pharmaceuticals to Market CLONICEL®; Up to $11 Million Alliance

  7/12/2007